Difference between revisions of "Perifosine (KRX-0401)"
Jump to navigation
Jump to search
m |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 5: | Line 5: | ||
===[[Hodgkin lymphoma]]=== | ===[[Hodgkin lymphoma]]=== | ||
| − | # Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. [Epub ahead of print] [http://clincancerres.aacrjournals.org/content/20/22/5641.full link to original article] [ | + | # Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. [Epub ahead of print] [http://clincancerres.aacrjournals.org/content/20/22/5641.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25239609 PubMed] |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 02:52, 2 December 2016
Mechanism of action
AKT and PI3K inhibitor
Preliminary data
Hodgkin lymphoma
- Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. [Epub ahead of print] link to original article PubMed
History of changes in FDA indication
- 9/3/2009: Received FDA orphan drug designation for treatment of multiple myeloma.
- 7/9/2010: Received FDA orphan drug designation for treatment of neuroblastoma.